169 related articles for article (PubMed ID: 21506148)
1. Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging.
Cho ZH; Oh SH; Kim JM; Park SY; Kwon DH; Jeong HJ; Kim YB; Chi JG; Park CW; Huston J; Lee KH; Jeon BS
Mov Disord; 2011 Mar; 26(4):713-8. PubMed ID: 21506148
[TBL] [Abstract][Full Text] [Related]
2. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
[TBL] [Abstract][Full Text] [Related]
3. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease.
Kwon DH; Kim JM; Oh SH; Jeong HJ; Park SY; Oh ES; Chi JG; Kim YB; Jeon BS; Cho ZH
Ann Neurol; 2012 Feb; 71(2):267-77. PubMed ID: 22367998
[TBL] [Abstract][Full Text] [Related]
4. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease.
Lehéricy S; Bardinet E; Poupon C; Vidailhet M; François C
Mov Disord; 2014 Nov; 29(13):1574-81. PubMed ID: 25308960
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
Wang C; Fan G; Xu K; Wang S
Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
[TBL] [Abstract][Full Text] [Related]
6. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease.
O'Neill J; Schuff N; Marks WJ; Feiwell R; Aminoff MJ; Weiner MW
Mov Disord; 2002 Sep; 17(5):917-27. PubMed ID: 12360540
[TBL] [Abstract][Full Text] [Related]
7. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.
Atasoy HT; Nuyan O; Tunc T; Yorubulut M; Unal AE; Inan LE
Neurol India; 2004 Sep; 52(3):332-7. PubMed ID: 15472421
[TBL] [Abstract][Full Text] [Related]
8. Asymmetrical diffusion tensor imaging indices of the rostral substantia nigra in Parkinson's disease.
Prakash BD; Sitoh YY; Tan LC; Au WL
Parkinsonism Relat Disord; 2012 Nov; 18(9):1029-33. PubMed ID: 22705126
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.
Geng DY; Li YX; Zee CS
Neurosurgery; 2006 Feb; 58(2):256-62; discussion 256-62. PubMed ID: 16462479
[TBL] [Abstract][Full Text] [Related]
10. [Magnetic resonance imaging in Parkinson's disease--the evaluation of the width of pars compacta on T2 weighted image].
Moriwaka F; Tashiro K; Itoh K; Hamada T; Miyasaka K
Rinsho Shinkeigaku; 1992 Jan; 32(1):8-12. PubMed ID: 1628441
[TBL] [Abstract][Full Text] [Related]
11. Inversion recovery MRI in idiopathic Parkinson disease is a very sensitive tool to assess neurodegeneration in the substantia nigra: preliminary investigation.
Raff U; Hutchinson M; Rojas GM; Huete I
Acad Radiol; 2006 Jun; 13(6):721-7. PubMed ID: 16679274
[TBL] [Abstract][Full Text] [Related]
12. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.
Martin WR; Wieler M; Gee M
Neurology; 2008 Apr; 70(16 Pt 2):1411-7. PubMed ID: 18172063
[TBL] [Abstract][Full Text] [Related]
13. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
[TBL] [Abstract][Full Text] [Related]
14. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts.
Michaeli S; Oz G; Sorce DJ; Garwood M; Ugurbil K; Majestic S; Tuite P
Mov Disord; 2007 Feb; 22(3):334-40. PubMed ID: 17149719
[TBL] [Abstract][Full Text] [Related]
15. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease.
Kashihara K; Shinya T; Higaki F
J Clin Neurosci; 2011 Aug; 18(8):1093-6. PubMed ID: 21719292
[TBL] [Abstract][Full Text] [Related]
16. [MRI in Parkinson's disease and vascular parkinsonism--study on the lesion of substantia nigra].
Aotsuka A; Shinotoh H; Hirayama K; Ikehira H; Fukuda H
Rinsho Shinkeigaku; 1991 Jun; 31(6):619-24. PubMed ID: 1934776
[TBL] [Abstract][Full Text] [Related]
17. The usage of proton magnetic resonance spectroscopy in Parkinson's disease.
Metarugcheep P; Hanchaiphiboolkul S; Viriyavejakul A; Chanyawattiwongs S
J Med Assoc Thai; 2012 Jul; 95(7):949-52. PubMed ID: 22919991
[TBL] [Abstract][Full Text] [Related]
18. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study.
Zhang J; Zhang Y; Wang J; Cai P; Luo C; Qian Z; Dai Y; Feng H
Brain Res; 2010 May; 1330():124-30. PubMed ID: 20303339
[TBL] [Abstract][Full Text] [Related]
19. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
[TBL] [Abstract][Full Text] [Related]
20. Detection of Parkinson's disease by MRI: Spin-lattice distribution imaging.
Hutchinson M; Raff U
Mov Disord; 2008 Oct; 23(14):1991-7. PubMed ID: 18759364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
